



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_35955
Title of the Manuscript:	Impact of ADAM17 expression as a potential prognostic biomarker and target for therapy in node-negative Breast Carcinoma
Type of the Article	Original Research Paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The authors have studied the role of MMP-like proteases ADAM (a disintegrin and metalloproteinase) 17 using IHC method in breast tumor tissue sections. They concluded that ADAM 17 independently has the prognostic role in node-negative breast cancer. They also conclude ADAM17 expression leads to differentiating indolent node-negative breast cancer from aggressive node-negative breast cancer. Concern to be addressed: Concluding ADAM 17 as a sole prognostic marker of aggressive and metastatic marker need to be supported by robust preclinical and clinical data, which the authors lack. Contradicting this conclusion, a recent paper (British Journal of Cancer (2015) 112, 1895–1903 doi: 10.1038/bjc.2015.163, “Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells” has shown elegantly that EGFR is one of the best-validated driver genes for TNBC. EGFR is normally activated following the release of ligands such as TGFα, mediated by the two MMP-like proteases ADAM (a disintegrin and metalloproteinase)-10 and ADAM-17. This reviewer would like to see the authors discuss the observations of the above article with respect to ADAM17 expression and lack of results (IHC) with regard to EGFR and ADAM-10 in breast tumor samples.	Please in the paper you referred us to, they were looking solely at the anti-tumor activity of ADAM17. Our current work specifically is centred on whether ADAM17 expression depends on the conventional prognostic factors, which has been worked on based on comments received from reviewers. But then, we did talk about its potential ability to serve as a prognostic marker and as target therapy based on other works elsewhere, which have been included in our introduction. We look forward to further our work in the area of therapeutic target and as a sole prognostic marker.
Minor REVISION comments	Discussion needs to be precise with relevant references	Please the discussion is modified Thank you
Optional/General comments	none	